Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.67 |
| ▸ | HPGDS | O60760 | 1/20 | 0.66 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.63 |
| ▸ | ALKBH1 | Q13686 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182164 | 0.87 | MAPKAPK2 (0.79) | EGLN1HPGDSALKBH2MEN1KMT2A | |
| SCHEMBL10998710 | 0.84 | EGLN1 (0.66) | EGLN1HPGDSALKBH2MEN1KMT2A | |
| SCHEMBL2852078 | 0.82 | ALKBH2 (0.72) | EGLN1HPGDSALKBH2RAB9AMAPT | |
| SCHEMBL9034514 | 0.81 | MEN1 (0.57) | EGLN1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL1330707 | 0.81 | XDH (0.58) | EGLN1 | |
| SCHEMBL15331859 | 0.81 | ALKBH2 (0.70) | EGLN1HPGDSALKBH2RAB9AMAPT | |
| SCHEMBL15578982 | 0.81 | HPGDS (0.60) | EGLN1HPGDSALKBH2ALKBH1 | |
| SCHEMBL14150633 | 0.81 | ALKBH1 (0.63) | EGLN1HPGDSALKBH2ALKBH1 | |
| SCHEMBL182309 | 0.80 | MAPKAPK2 (0.61) | EGLN1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL70281 | 0.80 | ALKBH2 (1.00) | EGLN1HPGDSALKBH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-11136297-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200131135-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-30 | — | — | US | disclosed |
| EP-2895477-B1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE. | HOFFMANN LA ROCHE (CH) | 2017-11-01 | — | — | EP | disclosed |
| US-9487501-B2 | Pyrazole carboxamide compounds and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150218131-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2895477-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014041007-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| EP-0540614-B1 | 3-(1-SUBSTITUTEDPYRAZOYL)-2-OXINDOLE DERIVATIVES | PFIZER (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0540614-A1 | 3-(1-SUBSTITUTEDPYRAZOYL)-2-OXINDOLE DERIVATIVES. | PFIZER (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001684-A1 | 3-(1-SUBSTITUTEDPYRAZOYL)-2-OXINDOLE DERIVATIVES | PFIZER INC. (US) | 1992-02-06 | — | — | WO | disclosed |
| US-5064851-A | Enzyme inhibitors, antiinflammatory | PFIZER INC. (US) | 1991-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131135-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HRAS, KRAS, NRAS | EGLN1 833/4885HPGDS 484/4885ALKBH2 1022/4885 |
| US-11136297-B2 | Compositions and methods for treating cancer | HRAS, KRAS, NRAS | EGLN1 833/4885HPGDS 484/4885ALKBH2 1022/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | EGLN1 2638/4885HPGDS 1109/4885ALKBH2 4440/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | EGLN1 2638/4885HPGDS 1109/4885ALKBH2 4440/4885 |
| US-20150218131-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | HCRTR1, TAAR1, HCRTR2 | EGLN1 2787/4885HPGDS 3652/4885ALKBH2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.